PMID- 23313392 OWN - NLM STAT- MEDLINE DCOM- 20130813 LR - 20181202 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 146 IP - 1 DP - 2013 Mar 7 TI - Ginsenosides Rg5 and Rh3 protect scopolamine-induced memory deficits in mice. PG - 294-9 LID - S0378-8741(13)00003-2 [pii] LID - 10.1016/j.jep.2012.12.047 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Panax ginseng (family Araliaceae) is traditionally used as a remedy for cancer, inflammation, stress and aging. AIM OF STUDY: To explore whether ginsenosides Rg5 and Rh3, the main constituents of heat-processed ginseng (the root of Panax ginseng), could protect memory deficit. MATERIALS AND METHODS: We isolated ginsenosides Rh3 and Rg5 from heated-processed ginseng treated with and without human feces, respectively. Then we investigated their protective effects on memory impairment using the passive avoidance, Y-maze and Morris water maze tasks in mice. Memory deficit was induced in mice by the intraperitoneal injection of scopolamine. RESULTS: Ginsenosides Rg5 or Rh3 increased the latency time reduced by scopolamine in passive avoidance test. Treatment with ginsenoside Rg5 or Rh3 significantly reversed the lowered spontaneous alteration induced by scopolamine in Y-maze task. Ginsenoisde Rg5 or Rh3 (10 mg/kg) significantly shortened the escape latencies prolonged by treatment with scopolamine on the last day of training trial sessions in Morris water maze task. Furthermore, ginsenosides Rg5 and Rh3 inhibited acetylcholinesterase activity in a dose-dependent manner, with IC50 values of 18.4 and 10.2 muM, respectively. The inhibitory potency of ginsenoside Rh3 is comparable with that of donepezil (IC50=9.9 muM). These ginsenosides also reversed hippocampal brain-derived neurotrophic factor (BDNF) expression and cAMP response element-binding protein (CREB) phosphorylation reduced by scopolamine. Of them, ginsenoside Rh3 more potently protected memory deficit. CONCLUSIONS: Ginsenoside Rg5 and its metabolite ginsenoside Rh3 may protect memory deficit by inhibiting AChE activity and increasing BDNF expression and CREB activation. CI - Copyright (c) 2013. Published by Elsevier Ireland Ltd. FAU - Kim, Eun-Jin AU - Kim EJ AD - Department of Life and Nanopharmaceutical Sciences, Kyung Hee University, 1, Hoegi, Dongdaemun-gu, Seoul 130-701, Republic of Korea. FAU - Jung, Il-Hoon AU - Jung IH FAU - Van Le, Thi Kim AU - Van Le TK FAU - Jeong, Jin-Ju AU - Jeong JJ FAU - Kim, Nam-Jae AU - Kim NJ FAU - Kim, Dong-Hyun AU - Kim DH LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130109 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Creb1 protein, mouse) RN - 0 (Cyclic AMP Response Element-Binding Protein) RN - 0 (Ginsenosides) RN - 0 (Neuroprotective Agents) RN - 0 (ginsenoside Rg5) RN - 105558-26-7 (ginsenoside Rh3) RN - DL48G20X8X (Scopolamine) RN - EC 3.1.1.7 (Acetylcholinesterase) SB - IM MH - Acetylcholinesterase/metabolism MH - Animals MH - Avoidance Learning/drug effects MH - Brain-Derived Neurotrophic Factor/metabolism MH - Cyclic AMP Response Element-Binding Protein/metabolism MH - Ginsenosides/pharmacology/*therapeutic use MH - Male MH - Maze Learning/drug effects MH - Memory Disorders/chemically induced/*drug therapy/metabolism/physiopathology MH - Mice MH - Mice, Inbred ICR MH - Neuroprotective Agents/pharmacology/*therapeutic use MH - Scopolamine EDAT- 2013/01/15 06:00 MHDA- 2013/08/14 06:00 CRDT- 2013/01/15 06:00 PHST- 2012/11/02 00:00 [received] PHST- 2012/12/27 00:00 [revised] PHST- 2012/12/29 00:00 [accepted] PHST- 2013/01/15 06:00 [entrez] PHST- 2013/01/15 06:00 [pubmed] PHST- 2013/08/14 06:00 [medline] AID - S0378-8741(13)00003-2 [pii] AID - 10.1016/j.jep.2012.12.047 [doi] PST - ppublish SO - J Ethnopharmacol. 2013 Mar 7;146(1):294-9. doi: 10.1016/j.jep.2012.12.047. Epub 2013 Jan 9.